跳至主要内容
临床试验/NCT01373372
NCT01373372撤回不适用

CRH Responsiveness in Children With Functional Dyspepsia: A Pilot Study

Children's Mercy Hospital Kansas City1 个研究点 分布在 1 个国家开始时间: 2016年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
1
主要终点
Heart rate variability

研究概览

简要总结

Chronic abdominal pain is the most common persistent pain condition in children and adolescents, affecting 10-15% of children at any given time. One of the most often diagnosed types of abdominal pain is functional dyspepsia (FD). FD is an abdominal pain or discomfort (e.g., nausea, bloating) in the upper abdomen that does not get better by going to the bathroom.

For some people it appears that stress can make FD worse. In adults, stress can cause the release of a hormone called corticotropin releasing hormone (CRH). The release of CRH can cause abdominal pain by affecting how fast things move through a person's stomach and intestines. This makes the organs in the abdomen more sensitive to pain, causing tenderness of the inside lining of the stomach and intestines.

Different people react differently when the body releases CRH. Some people have abdominal pain without feeling any stress or anxiety while other people who have a lot of stress or anxiety don't have any abdominal pain. Some people have neither stress, anxiety, or abdominal pain when CRH is released into the body.

In order to see how the bodies of children with functional dyspepsia and those without functional dyspepsia react to CRH, we will do a CRH stimulation test. A CRH stimulation test is routinely done in endocrine patients. It is not routinely done for patients with functional dyspepsia or for patients who do not have functional dyspepsia.

Part of the CRH stimulation test is giving a synthetic type of corticotropin, Acthrel® (brand name for Corticorelin), as injection. Acthrel® has been approved by the Food and Drug Administration (FDA) for use.

The purpose of this research study is to see if there are differences in how the bodies of children with functional dyspepsia react to CRH versus children who don't have functional dyspepsia.

Being in this study involves one clinic visit where an IV placed and a CRH stimulation test. In this test the child will be given an injection of CRH and then observed for one hour. During that hour the child will have five blood draws through the IV and will be asked questions about their anxiety and abdominal pain. This visit will take about 4 hours.

The following things will happen:

  • Your child will be asked to come to the clinic between 8a.m. and 10a.m. fasting. This means your child will have had nothing to eat or drink for 8 hours before coming to the clinic.
  • If your child is a female ten years of age or older, or has started having periods, a urine pregnancy test will be done before receiving the CRH infusion.
  • You and your child will each be asked to complete a survey that measures your child's anxiety.
  • Your child will have a biofeedback session that will measure your child's stress. In a biofeedback session, sensors are placed on your child's fingers, wrists and forehead. These sensors are connected to a computer that monitors your child's heartbeat, skin temperature and electrical pulses on your child's skin.
  • Your child will have an IV inserted into a vein in his/her arm. Your child may have a cream put on their arm to help with the pain of the IV insertion. The IV will be used to inject the CRH and draw blood. If the IV stops working and blood samples can no longer be drawn from it, your child may have another IV started or blood samples may be drawn by needle stick.
  • Your child will then have 30 minutes to relax.
  • Your child will then have CRH infused through the IV over one minute.
  • Your child will have blood drawn through the IV five times; right before the CRH stimulation test begins and 15, 30, 45 and 60 minutes after the CRH infusion. The total amount of blood drawn for the study will be about 2 ½ tablespoons.
  • Your child will be asked about their abdominal pain, nausea, bloating, stress and anxiety at three separate times during the 60 minutes.
  • Your child's heart rate will be measured throughout the CRH stimulation test.

详细描述

The primary purpose of this study is to evaluate whether there are differences in CRH (Corticotropin Releasing Hormone) responsiveness in children and adolescents with FD (Functional Dyspepsia) as compared to controls. Further, we intend to explore relationships between CRH responsiveness, inflammatory cytokines, state and trait anxiety, and self-reported symptoms.

The specific aims of the study are:

  1. To determine if changes in serum cytokine profiles, heart rate variability, stress profile parameters, state and trait anxiety, and self-reported symptoms differ between patients with FD and controls following CRH infusion.
  2. To determine if changes in serum ACTH (Adreno-corticotropic Hormone) or cortisol following CRH infusion differ between patients with FD and controls or as a function of the magnitude of state or trait anxiety among FD patients.

This study is a single-site pilot study.

Biochemical response to CRH stimulation will be explored for each of the cytokines, mediators and hormones detailed herein by calculating their rate of formation, maximal concentration (Cmax), time to maximal concentration (Tmax), total body exposure (AUC) and rate of recovery (as relevant). Pharmacokinetic analyses will be applied to data where there are clear ascending and descending phases on the concentration versus time profile. Concentration versus time data will be curve fit using a peeling algorithm to generate initial polyexponential parameter estimates. Final estimates of the apparent rate of recovery will be determined from an iterative, nonlinear weighted least squares regression algorithm. Assessment of goodness of fit for the pharmacokinetic model will be made using standard criteria (e.g., Akaike and Schwartz Information Criteria, objective function and the coefficients of variation for estimated parameters), the distribution of weighted residual estimates and the association between the observed and predicted concentrations. Model-independent pharmacokinetic parameters will be calculated using standard (i.e., statistical moment theory) techniques. Individual Cmax and Tmax will be estimated by inspection of the observed plasma concentration versus time data. The area under the plasma concentration versus time curve will be determined using the mixed log-linear trapezoidal rule (no extrapolation of the AUC to infinity will be performed). These analyses will be performed in Kinetica v5.0 (ThermoElectron, Philadelphia, PA). Differences between cases and controls on continuous response variables will be compared using a two-sided independent sample t-tests. Relationships among continuous response variables will be evaluated by univariate analysis of variance, linear and nonlinear regression techniques. Categorical patient factors and response variables will be compared with the Fisher's exact test on a 2 x 2 cross-tabulation. All statistical analyses will be conducted using the SSPS software package (version 15.0, SPSS Inc., Chicago, IL).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
8 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Group 1 (functional dyspepsia):
  • Ages 8-17 inclusive;
  • Abdominal pain of at least 8 weeks duration and fulfilling symptom-base criteria for FD;
  • Scheduled for endoscopy to evaluate dyspepsia following non-response to standard acid reduction therapy;
  • >20kg/45 lbs. and,
  • Group 2 (Controls):
  • Ages 8-17 inclusive;
  • >20kg/45 lbs.

排除标准

  • Both groups:
  • Previous abdominal surgery;
  • <20 kg/45 lbs.:
  • Pregnancy;
  • Chronic disease requiring regular medical care (e.g. diabetes mellitus, juvenile rheumatoid arthritis, cystic fibrosis, cancer); or,
  • Non-English speaking.
  • Controls:
  • Recent history (within 6 months) of abdominal pain, nausea, vomiting, diarrhea, constipation, or bloating based on parental and self-report.

研究组 & 干预措施

Functional Dyspepsia cohort

Experimental

Cohort of subjects with functional dyspepsia

干预措施: Acthrel (Drug)

Control cohort

Other

Control group of subjects with no functional dyspepsia

干预措施: Acthrel (Drug)

结局指标

主要结局

Heart rate variability

时间窗: Over 90 minutes

次要结局

  • Stress profile(over 90 minutes)
  • plasma protein levels(change over 60 minutes)
  • BASC 2 profile(change over 90 minutes)
  • STICSA-C(change over 90 minutes)
  • GI symptom severity scale(change over 90 minutes)

研究者

发起方
Children's Mercy Hospital Kansas City
申办方类型
Other
责任方
Principal Investigator
主要研究者

Craig A. Friesen, MD

Principal Investigator

Children's Mercy Hospital Kansas City

研究点 (1)

Loading locations...

相似试验

Corticotropin Releasing Hormone (CRH) Responsiveness... | 临床试验